Alphyn Biologics
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Dermatology
Alphyn is using its Zabalafin Drug Platform to develop unique Multi-Target Therapeutics® to be more efficacious and patient tolerable.
The Zabalafin Platform is an impactful innovation because it has multiple bioactive compounds with multiple mechanisms of action to treat individual diseases in multiple ways, to be more effective, and to treat multiple diseases. Our Platform drugs have strong safety, side effect, and patient tolerability profiles.
Company HQ City:
Annapolis
Company HQ State:
MD
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
Zabalafin
CEO
Neal Koller
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
Twlo
When you expect your next catalyst update?
12/2026
What is your next catalyst (value inflection) update?
Completion of two phase II clinical trial programs
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}